Nature Search

LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment

Immunoengineering-based cancer therapies have huge potential. Here the authors report on the lipid nanoparticle delivery, to cancer cells, of self-amplifying RNA encoding SARS-CoV-2 spike epitope-loaded MHC I molecules to take advantage of anti-SARS-CoV-2 immunity from a vaccinated population to treat cancer.

Yonger Xue
Xucheng Hou
Yizhou Dong
ResearchOpen Access04 Mar 2025
Nature Communications

Volume: 16, P: 1-13
Antimicrobial peptide delivery to lung as peptibody mRNA in anti-inflammatory lipids treats multidrug-resistant bacterial pneumonia

Antimicrobial peptides delivered to mouse lung as mRNA peptibodies eradicate multidrug-resistant pneumonia.

Yonger Xue
Xucheng Hou
Yizhou Dong
Research26 Nov 2025
Nature Biotechnology

P: 1-7
LNP-RNA-engineered adipose stem cells for accelerated diabetic wound healing

Adipose stem cells are promising therapeutic agents in tissue regeneration. Here the authors develop a lipid nanoparticle/RNA engineering platform to enhance the protein production of these cells, which demonstrate superior healing efficacy in a mouse model of diabetic cutaneous wounds.

Yonger Xue
Yuebao Zhang
Yizhou Dong
ResearchOpen Access25 Jan 2024
Nature Communications

Volume: 15, P: 1-13
Close the cancer–immunity cycle by integrating lipid nanoparticle–mRNA formulations and dendritic cell therapy

Overcoming the immunosuppressive tumour microenvironment is a challenge. A strategy to close the cancer–immunity cycle has been reported by integrating lipid nanoparticle–mRNA formulations and dendritic cell therapy to promote tumour elimination and develop antitumour immunity.

Yuebao Zhang
Xucheng Hou
Yizhou Dong
Research27 Jul 2023
Nature Nanotechnology

Volume: 18, P: 1364-1374
Blood–brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system

A lipid-nanoparticle-based formulation incorporating engineered lipids containing a blood–brain-barrier-crossing moiety effectively delivers mRNA to neurons and astrocytes following systemic administration in mice.

Chang Wang
Yonger Xue
Yizhou Dong
Research17 Feb 2025
Nature Materials

Volume: 24, P: 1653-1663
Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy

Antibodies targeting OX40 or CD137, two T cell costimulatory receptors, have been shown to improve antitumor immunity. Here the authors design a phospholipid-derived nanoparticle to deliver OX40 or CD137 mRNA to T cells in vivo, improving efficacy of anti-OX40 and anti-CD137 antibody therapy in preclinical tumor models.

Wenqing Li
Xinfu Zhang
Yizhou Dong
ResearchOpen Access14 Dec 2021
Nature Communications

Volume: 12, P: 1-12
The full annual carbon balance of a subtropical coniferous plantation is highly sensitive to autumn precipitation

Mingjie Xu
Huimin Wang
Wenjiang Zhang
ResearchOpen Access30 Aug 2017
Scientific Reports

Volume: 7, P: 1-12

Search

Filter By:

LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment

Antimicrobial peptide delivery to lung as peptibody mRNA in anti-inflammatory lipids treats multidrug-resistant bacterial pneumonia

LNP-RNA-engineered adipose stem cells for accelerated diabetic wound healing

Close the cancer–immunity cycle by integrating lipid nanoparticle–mRNA formulations and dendritic cell therapy

Blood–brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system

Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy

The full annual carbon balance of a subtropical coniferous plantation is highly sensitive to autumn precipitation

Search

Quick links